DrugMapper


Trade Names:	ACTOS PIOGLITAZONE PIOGLITAZONE HYDROCHLORIDE
Synonyms:	Actos Diabiom Glidipion Glizofar NSC-758876 Pioglitazone (as hydrochloride) Pioglitazone hcl Pioglitazone hydrochloride Piomed STR-001 U-72107A
Status:	Approved (1999)
Entry Type:	Small molecule
Molecule Category:	Salt
UNII:	JQT35NPK6C
Parent Compound:	PIOGLITAZONE


InChI Key	GHUUBYQTCDQWRA-UHFFFAOYSA-N
Smile	CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1.Cl
InChI	InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C19H21ClN2O3S
Molecular Weight	392.91
AlogP	3.16
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	7.0
Polar Surface Area	68.29
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	25.0

Action	Mechanism of Action	Reference
AGONIST	Peroxisome proliferator-activated receptor gamma agonist	DailyMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 1 Nuclear hormone receptor subfamily 1 group C Nuclear hormone receptor subfamily 1 group C member 3	490	-	-	-	-
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 2 Nuclear hormone receptor subfamily 2 group B Nuclear hormone receptor subfamily 2 group B member 1	490	-	-	-	-
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	123

Mesh Heading	Maximum Phase	Mesh ID	Reference
Carcinoma, Non-Small-Cell Lung	2	D002289	ClinicalTrials
Leukoplakia, Oral	2	D007972	ClinicalTrials
Renal Insufficiency, Chronic	2	D051436	ClinicalTrials
Depressive Disorder, Major	2	D003865	ClinicalTrials
Non-alcoholic Fatty Liver Disease	1	D065626	ClinicalTrials
Amyotrophic Lateral Sclerosis	1	D000690	ClinicalTrials
Pancreatic Neoplasms	0	D010190	ClinicalTrials

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Parent

Mixture

Side Effects from Label

Side Effects (PT)

Side effects	Relative Frequency (%)	Labels
Endocrine disorders Hypoglycaemia	30.6
Endocrine disorders Hypoglycaemia	27.3
General disorders and administration site conditions Oedema	26.7
Investigations Weight increased	26.2
Endocrine disorders Hypoglycaemia	24.1
Endocrine disorders Hypoglycaemia
General disorders and administration site conditions Oedema	15.8
General disorders and administration site conditions Oedema
Infections and infestations Upper respiratory tract infection	13.2
Nervous system disorders Headache	9.1
Infections and infestations Respiratory tract infection	8.9
Infections and infestations Upper respiratory tract infection	8.9
Infections and infestations Upper respiratory tract infection	8.7
Infections and infestations Upper respiratory tract infection
Cardiac disorders Cardiac failure	8.1
Endocrine disorders Diabetes mellitus
Investigations Weight increased	7.8
Endocrine disorders Hypoglycaemia
Infections and infestations Respiratory tract infection	7.5
Infections and infestations Upper respiratory tract infection	7.5
Infections and infestations Upper respiratory tract infection
Endocrine disorders Hypoglycaemia
Nervous system disorders Headache	7.0
General disorders and administration site conditions Oedema	7.0
Nervous system disorders Headache
Gastrointestinal disorders Diarrhoea
Nervous system disorders Headache
Musculoskeletal and connective tissue disorders Pain in extremity	6.4
Infections and infestations Sinusitis	6.3
Infections and infestations Respiratory tract infection
Infections and infestations Upper respiratory tract infection
Cardiac disorders Cardiac failure
Musculoskeletal and connective tissue disorders Back pain	5.9
Endocrine disorders Hypoglycaemia	5.9
Cardiac disorders Cardiac failure congestive	5.72
Musculoskeletal and connective tissue disorders Pain in extremity
Musculoskeletal and connective tissue disorders Back pain	5.5
Investigations Weight increased	5.5
Musculoskeletal and connective tissue disorders Arthralgia	5.4
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort	5.4
Musculoskeletal and connective tissue disorders Myalgia	5.4
Gastrointestinal disorders Tooth disorder	5.3
Musculoskeletal and connective tissue disorders Back pain
Cardiac disorders Chest pain	5.1
Endocrine disorders Diabetes mellitus	5.1
Nervous system disorders Headache	5.1
Gastrointestinal disorders Pharyngitis	5.1
Cardiac disorders Chest pain
Musculoskeletal and connective tissue disorders Arthralgia	4.8
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort	4.8
Gastrointestinal disorders Diarrhoea	4.6
Infections and infestations Sinusitis
Nervous system disorders Headache	4.2
General disorders and administration site conditions Asthenia	4.1
Cardiac disorders Cardiac failure congestive
Musculoskeletal and connective tissue disorders Back pain
Musculoskeletal and connective tissue disorders Back pain	3.7
Infections and infestations Sinusitis	3.6
Musculoskeletal and connective tissue disorders Back pain	3.5
Cardiac disorders Oedema peripheral	3.5
Cardiac disorders Oedema peripheral
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort	3.2
Musculoskeletal and connective tissue disorders Myalgia	3.2
General disorders and administration site conditions Oedema	3.2
Musculoskeletal and connective tissue disorders Arthralgia
Musculoskeletal and connective tissue disorders Arthralgia	3.1
Musculoskeletal and connective tissue disorders Back pain	3.1
Nervous system disorders Headache
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort	3.1
Infections and infestations Sinusitis
Infections and infestations Bronchitis	2.8
General disorders and administration site conditions Discomfort	2.8
General disorders and administration site conditions Feeling abnormal	2.8
Nervous system disorders Headache	2.8
General disorders and administration site conditions Ill-defined disorder	2.8
General disorders and administration site conditions Malaise	2.8
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort	2.8
Musculoskeletal and connective tissue disorders Myalgia	2.8
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort
Musculoskeletal and connective tissue disorders Myalgia
Gastrointestinal disorders Pharyngitis	2.7
Infections and infestations Urinary tract infection	2.7
General disorders and administration site conditions Oedema
Gastrointestinal disorders Tooth disorder	2.6
General disorders and administration site conditions Asthenia	2.5
Gastrointestinal disorders Diarrhoea	2.5
General disorders and administration site conditions Fatigue	2.5
General disorders and administration site conditions Asthenia
General disorders and administration site conditions Fatigue
Musculoskeletal and connective tissue disorders Back pain
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort
Musculoskeletal and connective tissue disorders Myalgia
Gastrointestinal disorders Tooth disorder
Injury, poisoning and procedural complications Injury	2.2
Gastrointestinal disorders Abdominal pain upper	2.1
Gastrointestinal disorders Diarrhoea	2.1
Gastrointestinal disorders Gastroenteritis	2.1
Infections and infestations Influenza	2.1
Musculoskeletal and connective tissue disorders Muscle spasms	2.1
Gastrointestinal disorders Tooth abscess	2.1
Eye disorders Visual impairment	2.1
Musculoskeletal and connective tissue disorders Arthralgia
General disorders and administration site conditions Asthenia
Musculoskeletal and connective tissue disorders Back pain
Infections and infestations Bronchitis
Gastrointestinal disorders Diarrhoea
Nervous system disorders Headache
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort
Infections and infestations Urinary tract infection
Injury, poisoning and procedural complications Injury
Gastrointestinal disorders Tooth disorder
Eye disorders Visual impairment
General disorders and administration site conditions Discomfort
General disorders and administration site conditions Feeling abnormal
Gastrointestinal disorders Gastroenteritis
General disorders and administration site conditions Ill-defined disorder
General disorders and administration site conditions Malaise
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort
Musculoskeletal and connective tissue disorders Myalgia
Investigations Weight increased
Musculoskeletal and connective tissue disorders Muscle spasms
Investigations Weight increased
Gastrointestinal disorders Pharyngitis
Gastrointestinal disorders Abdominal pain upper
Infections and infestations Influenza
General disorders and administration site conditions Oedema
Gastrointestinal disorders Pharyngitis

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Renal and urinary disorders	34.33
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	31.16
General disorders and administration site conditions	7.12
Cardiac disorders	3.35
Investigations	2.75
Gastrointestinal disorders	2.65
Metabolism and nutrition disorders	2.36
Musculoskeletal and connective tissue disorders	2.31
Vascular disorders	2.08

Resources	Reference
ChEBI	8229
ChEMBL	CHEMBL1715
EPA CompTox	DTXSID3044203
FDA SRS	JQT35NPK6C
PubChem	60560
SureChEMBL	SCHEMBL21843

PIOGLITAZONE HYDROCHLORIDE

Structure

Physicochemical Descriptors

Pharmacology

Indications

Related Entries

Scaffolds

Side Effects from Label

Adverse Reactions

Cross References


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70